Skip to Content
Merck
All Photos(1)

Key Documents

More Documents

D0740000

Dextromethorphan hydrobromide

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Dextromethorphan hydrobromide monohydrate, (9S,13S,14S)-3-Methoxy-17-methylmorphinan hydrobromide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C18H25NO · HBr · H2O
CAS Number:
6700-34-1
Molecular Weight:
370.32
Beilstein:
6453793
MDL number:
MFCD02173901
UNSPSC Code:
41116107
PubChem Substance ID:
329798635
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

dextromethorphan

manufacturer/tradename

EDQM

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

Br[H].[H]O[H].[H][C@]12CCCC[C@]13CCN(C)[C@H]2Cc4ccc(OC)cc34

InChI

1S/C18H25NO.BrH.H2O/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18;;/h6-7,12,15,17H,3-5,8-11H2,1-2H3;1H;1H2/t15-,17+,18+;;/m1../s1

InChI key

STTADZBLEUMJRG-IKNOHUQMSA-N

Gene Information

human ... GRIN2A(2903) , SIGMAR1(10280)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Dextromethorphan hydrobromide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Skull and crossbonesEnvironment
GHS06,GHS09

Signal Word

Danger

Hazard Statements

H301,H411

Hazard Classifications

Acute Tox. 3 Oral - Aquatic Chronic 2

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Melanie A Paquette et al.
The European journal of neuroscience, 36(9), 3224-3234 (2012-08-07)
Amantadine and dextromethorphan suppress levodopa (L-DOPA)-induced dyskinesia (LID) in patients with Parkinson's disease (PD) and abnormal involuntary movements (AIMs) in the unilateral 6-hydroxydopamine (6-OHDA) rat model. These effects have been attributed to N-methyl-d-aspartate (NMDA) antagonism. However, amantadine and dextromethorphan are
Tao-Cheng Wu et al.
PloS one, 7(9), e46067-e46067 (2012-10-11)
Vascular oxidative stress may be increased with age and aggravate endothelial dysfunction and vascular injury in hypertension. This study aimed to investigate the effects of dextromethorphan (DM), a NADPH oxidase inhibitor, either alone or in combination treatment, on blood pressure
Fixed drug eruption due to dextromethorphan with tolerance to other opioids.
G Davila-Fernández et al.
Journal of investigational allergology & clinical immunology, 23(4), 281-282 (2013-08-24)
K N Chi et al.
Cancer chemotherapy and pharmacology, 71(1), 237-244 (2012-10-16)
To assess the effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan HBr (CYP2D6 substrate) and theophylline (CYP1A2 substrate) in patients with metastatic castration-resistant prostate cancer (mCRPC). Men with progressive metastatic mCRPC who failed gonadotropin-releasing hormone therapy and
Muneaki Matsuo et al.
Pediatric neurology, 48(3), 200-205 (2013-02-20)
Acute encephalopathy with biphasic seizures and late reduced diffusion was recently established clinicoradiologically as an encephalopathy syndrome. The outcome of this encephalopathy is characterized by a low mortality rate and high incidence of neurologic sequelae. Although the exact pathogenesis of
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service